ReviewHaematologica2019
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
Review in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of dapsone in adult immune thrombocytopenia: a systematic review and meta-analysis.European journal of medical research · 2025Pooled it
- Efficacy and safety of mycophenolate mofetil in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis.Clinical rheumatology · 2024Pooled it
- Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.Annals of hematology · 2026Trial
- Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.BMJ (Clinical research ed.) · 2025Trial
- Overuse of thrombopoietin receptor agonists driven by suboptimal response is associated with myelofibrosis in pediatric immune thrombocytopenia.Haematologica · 2026Article
- Therapeutic Plasma Exchange in Immune-Mediated Thrombotic Thrombocytopenic Purpura: From Cornerstone to Contextualized Therapy.Journal of clinical medicine · 2026Review
- When Platelet Stimulation Becomes Marrow Stress: Rethinking Thrombopoietin Receptor Agonist Intensification in Pediatric Immune Thrombocytopenia.Pediatric reports · 2026Article
- Recombinant haemostatic protein for therapeutic substitution of platelet function via tripartite haemostatic mechanisms in thrombocytopenic male mice.Nature communications · 2026Article
- Patient and Physician Experiences in Immune Thrombocytopenia.Advances in therapy · 2026Article
- Platelet Disorders and Medication Strategies.Thrombosis and haemostasis · 2026Review
- Efficacy and safety of immunosuppressive therapy in connective tissue disease-related immune thrombocytopenia: a systematic review and meta-analysis.Therapeutic advances in hematology · 2026Article
- Limitations of rituximab in treating primary immune thrombocytopenia and the therapeutic potentials of alternatives.Current opinion in hematology · 2026Review
- Refractory ITP: revisiting definitions, diagnostics, and management paradigms.Hematology. American Society of Hematology. Education Program · 2025Review
- Venous thromboembolism in bullous pemphigoid: current evidence from an updated systematic review.Dermatology reports · 2025Article
- Urinary metabolomics predicts early rituximab response in steroid-nonresponsive pediatric patients with primary immune thrombocytopenia.Annals of hematology · 2025Article
- Splenectomy in Onco-Hematologic Patients: A Retrospective Study of Early Complications and 1-Year Mortality.Cancers · 2025Article
- Navigating Severe Thrombocytopenia in End-Stage Liver Disease: A Pre-transplant Management Dilemma.Cureus · 2025Article
- Cytopenias in Autoimmune Liver Diseases-A Review.Journal of clinical medicine · 2025Review
- Combination of anti-CD20 and hetrombopag in relapsed/refractory immune thrombocytopenia: a case series.Frontiers in medicine · 2025Article
- Predictors for spontaneous remission in childhood chronic immune thrombocytopenia.Annals of hematology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it led to up to 60% response rates, making it, nearly 20 years ago, the main alternative to splenectomy, with far fewer side effects. However, long-term follow-up data showed that only 20-30% of patients maintained the remission. No significant changes have been registered using different dose schedules and timing of administration, while the combination with other drugs seemed promising. Higher response rates have been observed in young women before the chronic phase, but apart from that, other clinical factors or biomarkers predictive of response are still lacking. In this review we examine the historical and current role of rituximab in the management of immune thrombocytopenia, 20 years after its first use for the treatment of autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.